Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2017

Open Access 01-12-2017 | Research

Characteristics of glucose metabolism indexes and continuous glucose monitoring system (CGMS) in patients with insulinoma

Authors: Weijun Gu, Yixin Liu, Hongyan Liu, Guoqing Yang, Qinghua Guo, Jin Du, Nan Jin, Li Zang, Zhaohui Lv, Jianming Ba, Yiming Mu, Jingtao Dou

Published in: Diabetology & Metabolic Syndrome | Issue 1/2017

Login to get access

Abstract

Aims

Analyze the clinical applicability of glucose metabolism indexes and continuous glucose monitoring data on the qualitative diagnosis of insulinoma.

Methods

Involve 22 patients with insulinoma (insulinoma group), 11 patients with hypoglycemia (hypoglycemia group) and 31 people with normal glucose tolerance (control group). HbA1c, fasting blood glucose (FBG), insulin (FINS) and C-peptide (FCP) was tested. Using CGMS to monitor the blood glucose for three consecutive days and selecting the monitoring data of 24 h thereof, figuring out, with the aid of EasyGV Version 9.0, the mean glucose (MG), the standard deviation (SD) of blood glucose, CONGA (continuous overall net glycemic action), J-Index, LI (Lability Index), LBGI (Low Blood Glucose Index), HBGI (High Blood Glucose Index), GRADE (glycaemic risk assessment diabetes equation), MAGE (mean aplitude of glycaemic excursions), M value, MAG (mean absolute glucose).

Results

(1) FBG and LBG of insulinoma group are lower than those of control group and those of hypoglycemia group while FINS and FCP of insulinoma group are markedly higher than those of the other two groups; (2) the MG and CONGA of insulinoma group are lower than those of control group and its indexes like ST, LI, LBGI, GRADE, MAGE, M value and MAG are higher than those of control group; there are differences between the indexes of insulinoma group and those of hypoglycemia group in CONGA (lower than that of hypoglycemia group), LBGI (higher than that of hypoglycemia group), and M value (higher than that of hypoglycemia group). By drawing the ROC curve and calculating Youden index, the cut-off values of LBGI, M value, CONGA are respectively as 4.06, 7.79, 4.38, and the best index of differential diagnosis is LBGI.

Conclusion

Continuous glucose monitoring data can be used to diagnose insulinoma and blood glucose fluctuation indicators such as LBGI, M value, CONGA might be useful to identify insulinoma.
Literature
1.
go back to reference Service FJ, Dale AJ, Elveback LR, Jiang NS. Insulinoma: clinical and diagnostic features of 60 consecutive cases. Mayo Clin Proc. 1976;51:417–29.PubMed Service FJ, Dale AJ, Elveback LR, Jiang NS. Insulinoma: clinical and diagnostic features of 60 consecutive cases. Mayo Clin Proc. 1976;51:417–29.PubMed
2.
go back to reference Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer. 2008;15:409–27.CrossRefPubMedPubMedCentral Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer. 2008;15:409–27.CrossRefPubMedPubMedCentral
3.
go back to reference Hirshberg B, Livi A, Bartlett DL, Libutti SK, Alexander HR, Doppman JL, Skarulis MC, Gorden P. Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab. 2000;85:3222–6.CrossRefPubMed Hirshberg B, Livi A, Bartlett DL, Libutti SK, Alexander HR, Doppman JL, Skarulis MC, Gorden P. Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab. 2000;85:3222–6.CrossRefPubMed
4.
go back to reference Hirshberg B, Cochran C, Skarulis MC, Libutti SK, Alexander HR, Wood BJ, Chang R, Kleiner DE, Gorden P. Malignant insulinoma: spectrum of unusual clinical features. Cancer. 2005;104:264–72.CrossRefPubMedPubMedCentral Hirshberg B, Cochran C, Skarulis MC, Libutti SK, Alexander HR, Wood BJ, Chang R, Kleiner DE, Gorden P. Malignant insulinoma: spectrum of unusual clinical features. Cancer. 2005;104:264–72.CrossRefPubMedPubMedCentral
5.
go back to reference Han J, Zhang F, Bao YQ, et al. Diagnostic value of parameters of glucose metabolism as screening tests for insulinoma. Natl Med J China. 2010;90(16):1093–6. Han J, Zhang F, Bao YQ, et al. Diagnostic value of parameters of glucose metabolism as screening tests for insulinoma. Natl Med J China. 2010;90(16):1093–6.
6.
go back to reference Liu M, Mu Y, Pan C. Advances in diagnosis and treatment of insulinoma. China J Pract Intern Med. 2006;26(22):1767–9. Liu M, Mu Y, Pan C. Advances in diagnosis and treatment of insulinoma. China J Pract Intern Med. 2006;26(22):1767–9.
7.
go back to reference Suzuki K, Miyamoto M, Miyamoto T, Hirata K. Insulinoma with early-morning abnormal behavior. Intern Med. 2007;46:405–8.CrossRefPubMed Suzuki K, Miyamoto M, Miyamoto T, Hirata K. Insulinoma with early-morning abnormal behavior. Intern Med. 2007;46:405–8.CrossRefPubMed
8.
go back to reference Maestri M, Monzani F, Bonanni E, et al. Insulinoma presenting as idiopathic hypersomnia. Neurol Sci. 2010;31:349–52.CrossRefPubMed Maestri M, Monzani F, Bonanni E, et al. Insulinoma presenting as idiopathic hypersomnia. Neurol Sci. 2010;31:349–52.CrossRefPubMed
9.
go back to reference Kawasakia A, Suzukia K, Miyamotoa M, Miyamotob T, Yanagic K, Shimizuc M, Hirataa K. Disruptive nocturnal behavior due to insulinoma revealed by continuous glucose monitoring. Eur J Neurol. 2014;21:e46–7.CrossRef Kawasakia A, Suzukia K, Miyamotoa M, Miyamotob T, Yanagic K, Shimizuc M, Hirataa K. Disruptive nocturnal behavior due to insulinoma revealed by continuous glucose monitoring. Eur J Neurol. 2014;21:e46–7.CrossRef
10.
go back to reference Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes. 2005;54:3592–601.CrossRefPubMed Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes. 2005;54:3592–601.CrossRefPubMed
11.
go back to reference Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes. 1991;40:223–6.CrossRefPubMed Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes. 1991;40:223–6.CrossRefPubMed
12.
go back to reference Cryer PE. Hypoglycemia in diabetes: pathophysiological mechanisms and diurnal variation. Prog Brain Res. 2006;153:361–5.CrossRefPubMed Cryer PE. Hypoglycemia in diabetes: pathophysiological mechanisms and diurnal variation. Prog Brain Res. 2006;153:361–5.CrossRefPubMed
13.
go back to reference Ding B, Sun R, Shen Y, et al. Application of continuous glucose monitoring system to explore the blood glucose fluctuation model of insulinoma. China Med Herald. 2013;10(29):57–8. Ding B, Sun R, Shen Y, et al. Application of continuous glucose monitoring system to explore the blood glucose fluctuation model of insulinoma. China Med Herald. 2013;10(29):57–8.
14.
go back to reference Munir A, Choudhary P, Harrison B, Heller S, Newell-Price John. Continuous glucose monitoring in patients with insulinoma. Clin Endocrinol. 2008;68:912–8.CrossRef Munir A, Choudhary P, Harrison B, Heller S, Newell-Price John. Continuous glucose monitoring in patients with insulinoma. Clin Endocrinol. 2008;68:912–8.CrossRef
15.
go back to reference Maia FF, Araujo LR. Efficacy of continuous gluco tem (CGMS) to detect postprandial hyperglycemia and unrecognized hypoglycemia in type 1 diabetic patients. Diabetes Res Clin Pract. 2007;75(1):30–4.CrossRefPubMed Maia FF, Araujo LR. Efficacy of continuous gluco tem (CGMS) to detect postprandial hyperglycemia and unrecognized hypoglycemia in type 1 diabetic patients. Diabetes Res Clin Pract. 2007;75(1):30–4.CrossRefPubMed
16.
go back to reference Maia FF, Araujo LR. Efficacy of continuous glucose monitoring system to detect unrecognized hypoglycemia in children and adolescents with type 1 diabetes. Arg Bras Endocrinol Metabol. 2005;49(4):569–74.CrossRef Maia FF, Araujo LR. Efficacy of continuous glucose monitoring system to detect unrecognized hypoglycemia in children and adolescents with type 1 diabetes. Arg Bras Endocrinol Metabol. 2005;49(4):569–74.CrossRef
17.
go back to reference Hoi-Hansen T, Pedersen-Bjergaard U, Thorsteinsson B. Reproducibility and reliability of hypoglycaemic episodes recorded with continuous glucose monitoring system (CGMS) in daily life. Diabet Med. 2005;22:858–62.CrossRefPubMed Hoi-Hansen T, Pedersen-Bjergaard U, Thorsteinsson B. Reproducibility and reliability of hypoglycaemic episodes recorded with continuous glucose monitoring system (CGMS) in daily life. Diabet Med. 2005;22:858–62.CrossRefPubMed
18.
go back to reference McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther. 2005;7:253–63.CrossRefPubMed McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther. 2005;7:253–63.CrossRefPubMed
Metadata
Title
Characteristics of glucose metabolism indexes and continuous glucose monitoring system (CGMS) in patients with insulinoma
Authors
Weijun Gu
Yixin Liu
Hongyan Liu
Guoqing Yang
Qinghua Guo
Jin Du
Nan Jin
Li Zang
Zhaohui Lv
Jianming Ba
Yiming Mu
Jingtao Dou
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2017
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-017-0215-3

Other articles of this Issue 1/2017

Diabetology & Metabolic Syndrome 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.